## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applica	nt(s):	Fernando Albericio Palomera				
Serial N	o.:	10/570,734	Group Art Unit:	1654		
Filed:		October 18, 2006	Examiner: Confirmation No:	Ronald T. Niebauer 7206		
For:		New Antitumoral Compounds				
P.O. Bo	x 1450	for Patents A 22313-1450				
	SU	PPLEMENTAL INFORMATIO	N DISCLOSURE S	<u> FATEMENT</u>		
Sir:						
		This Information Disclosure Staten	nent is filed in accord	ance with 37 C.F.R.		
§§1.56,	1.97 ar	d 1.98. The items listed on Form I	PTO-1449, a copy of	which is enclosed, are		
made of	record	to assist the Patent and Trademark	Office in its examina	tion of this application.		
The Exa	miner	is respectfully requested to fully co	nsider the items and t	o independently ascertain		
their tea	ching.					
1.	not i	For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:				
2.	not i	or each of the following items listed on the enclosed copy of Form PTO-1449 that is of in the English language, a concise explanation of the relevance of that item is acorporated in the specification of the above-identified application.				
3.	encle	only copy of the items listed on the enclosed copy of Form PTO-1449 that is not no closed with this Information Disclosure Statement was previously cited by or ubmitted to the Patent and Trademark Office in application Serial No, filed				
		_				
4.		fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement e it is being filed in compliance with:				
		37 C.F.R. §1.97(b)(1), within th application other than a CPA; or		ng date of a national		
		37 C.F.R. §1.97(b)(2), within th national stage as set forth in §1.				

US 10/570,734 Docket No. 13566.105010

			37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or	
			$37$ C.F.R. $\S 1.97 (b) (4)$ before the mailing date of a first office action after the filing of an RCE under $\S 1.114.$	
5.		No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specific in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one o the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.		
6.		it is be	Fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since s being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in agraph 4 above but before the mailing date of a final action or a notice of owance (where there has been no prior final action):	
			A check in the amount of \$180.00 is enclosed in payment of the fee.	
			Charge the fee to Deposit Account No. <u>50-3732</u> , Order No	
7.	it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing de		is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since eing filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final or a notice of allowance, whichever comes first, but before payment of the issue id is accompanied by:	
			ne of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 elow; and	
			e fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 clow.	
8.		This Information Disclosure Statement is being filed in compliance with:		
		a. 🗌	37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);	
		b. 🗌	$37\ C.F.R.\ \$1.313(c)(2)$ or $\$1.313(c)(3)$ , after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. $\$1.17(h)$ .	
		c. 🗌	The fee due under 37 C.F.R. $\$\$1.17(h)$ is paid as set forth in paragraph $11$ below.	
9.			by certify that each item of information contained in this Information Disclosure a net was first cited in a communication from a foreign patent office in a	

-2-

US 10/570,734 Docket No. 13566.105010

	counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.  I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.						
10.	This document is accompanied by $\square$ a Search Report $\square$ Communication which was cited in a corresponding $\square$ PCT or $\square$ Foreign counterpart application.						
11.	A check in the amount of \$ c.F.R. §§1.17(h) and 1.17(p).						
	Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 50-3732, Order No						
	The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-3732, Order No. 13566.105010.						
			Respectfully submitted, KING & SPALDING LLP				
Date: March 11, 2009 By:			/michael willis/ Kenneth H. Sonnenfeld / Michael A. Willis Reg. No. 33,285 / Reg. No. 53,913				
Correspo	ndence Address:	1105.110100,200					
King & Spalding LLP							
1185 Avenue of the Americas							
New York, NY 10036							
212-556-2100 Telephone							
212-556-2222 Facsimile							

1039288 -3-